Biotechnology

Kiromic Biopharma

Kiromic Biopharma released FY2024 annual earnings on February 14 (EST), with actual revenue of 0 USD and EPS of -3.1665 USD

Kiromic Biopharma released FY2024 Q4 earnings on February 14, 2025 (EST), with actual revenue of 0 USD and EPS of 13.1344 USD

Kiromic Biopharma released FY2024 Q3 earnings on November 8, 2024 (EST) with actual revenue of 0 and EPS of -6.1167

Kiromic Biopharma released FY2024 9 Months Earnings on November 8, 2024 (EST) with actual revenue of 0 and EPS of -17.1164

Kiromic Biopharma Advances Deltacel-01 to Expansion Phase Based on Safety Monitoring Committee Recommendation

FDA Grants Fast Track Designation to Kiromic BioPharma

Kiromic Biopharma Lists UPMC as Fourth DeltaCel-01 Clinical Trial Site

Kiromic Biopharma released FY2023 Q4 earnings on March 19 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS 3.167 USD (forecast -14.7 USD)

Kiromic Biopharma released FY2023 Annual Earnings on March 19 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -12.588 USD (forecast -46.5 USD)

Kiromic Biopharma released FY2023 Cumulative 3Q Earnings on November 14 (EST), Revenue: 0, EPS: -17.432

Top Wealth

Orangekloud Tech

Wave Life Sciences

Cemtrex

Webuy Global

Structure Therapeutics

Biodexa Pharmaceuticals

Creative Media & Community Trust

Fulcrum Therapeutics

Kymera Therapeutics

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap